Aripiprazole Tablet
Product Images NDC 76282-044
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 76282-044). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Exelan Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aripiprazole15mg30's (Aripiprazole15mg30s)
This is a description for a medication called Aripiprazole, which is available in tablet form and manufactured by Exelan. The tablets come in different dosages ranging from 5mg to 15mg, and the recommended dosage can be found on the packaging. The medication should be stored in a cool, dry place, and the container should be kept closed. The manufacturer is Erlon Pharmaceuticals located in Nanso, Sweden, and the distributor is Ascont Pharmaceuticals located in Conalip, France.*
Aripiprazole20mg30's (Aripiprazole20mg30s)
Aripiprazole2mg30's (Aripiprazole2mg30s)
Aripiprazole30mg30's (Aripiprazole30mg30s)
Aripiprazole5mg30's (Aripiprazole5mg30s)
Figure-6 (Figure 6)
Figure1 (Figure1)
This is a table showing the effect of different drugs on the metabolism of aripiprazole, a medication used to treat various mental disorders. The drugs are classified based on their ability to either inhibit or induce certain enzymes in the liver that are responsible for breaking down aripiprazole. The fold change and 90% confidence intervals of aripiprazole levels in the blood are also provided. The drugs tested include ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*
Figure2 (Figure2)
This is a table showing the effect of various drugs on aripiprazole, with information on whether they are CYP3A4 inhibitors or inducers, CYP2D6 inhibitors, gastric acid blockers, or other drugs. The table also shows a fold change and a 90% confidence interval for dehydro-aripiprazole relative to a reference without interacting drugs, with values ranging from 0 to 30.*
Figure3 (Figure3)
Figure4 (Figure4)
This appears to be a table summarizing the effects of various factors (such as PK, gender, age, and hepatic/renal impairment) on the pharmacokinetics of a drug called Avripiprazole. The table includes information on changes in AUC and maximum concentration (max) for different groups of patients compared to a reference group. However, without additional context or data, it's difficult to determine the specific implications of these findings.*
Figure5 (Figure5)
This appears to be a table that includes information about different factors such as PK, CYP2D6, Gender, Age, Hepatic Impairment, and Renal Impairment, and their effect on AUC and maximum Vel. However, there is not enough context and the text is not complete, making it difficult to generate a useful description.*
Structure (Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.